person · Reporting owner

Gangolli Julian S

Disclosed activity across 4 companies

Tapewire entity: 74543
SEC CIK: 0001532023

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Krystal Biotech, Inc.KRYS · Entity 3500	Director	September 14, 2026	September 17, 2026
Outlook Therapeutics, Inc.OTLK · Entity 608	Director	October 01, 2025	October 03, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Krystal Biotech, Inc.

Report date September 14, 2026 · Filed September 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $340.03 · Expires 2036-09-13	Direct	1,187	Reported balance After 2026-09-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-14 · Grant · Acquired 1,187 · Balance 1,187 F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	471	Reported balance After 2026-09-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-14 · Grant · Acquired 471 · Balance 471 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3: The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Outlook Therapeutics, Inc.

Report date October 01, 2025 · Filed October 03, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2035-10-01	Direct	286,734	Reported balance After 2025-10-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-10-01 · Grant · Acquired 286,734 · Balance 286,734 F1: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Filing footnotes · ownership attribution and instrument terms

F1: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

GW PHARMACEUTICALS PLC

Report date May 10, 2019 · Filed May 14, 2019

Section 16 reporting ended · disclosed 2019-05-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	106,548	Ending reported balance After 2019-05-10 transaction · row 11 11 source rows · reconciled sequence Row 1 · 2019-05-10 · Exercise / conversion · Acquired 403,804 · Balance 510,352 F1: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019. Row 2 · 2019-05-10 · Exercise / conversion · Acquired 75,369 · Balance 585,721 F1: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3: The exercise price was previously reported to be $8.7364 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error. Row 3 · 2019-05-10 · Exercise / conversion · Acquired 192,755 · Balance 778,476 F1: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F4: The exercise price was previously reported to be $3.3461 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error. Row 4 · 2019-05-10 · Sale · Disposed 117,876 · Balance 660,600 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F6: The price reported in Column 4 is a weighted average price per ordinary share ($175.57 per ADS). These shares were sold in multiple transactions at prices ranging from $174.99 per ADS (or $14.58 per ordinary share) to $175.98 per ADS (or $14.67 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2019-05-10 · Sale · Disposed 81,156 · Balance 579,444 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F7: The price reported in Column 4 is a weighted average price per ordinary share ($176.40 per ADS). These shares were sold in multiple transactions at prices ranging from $175.99 per ADS (or $14.67 per ordinary share) to $176.87 per ADS (or $14.74 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 6 · 2019-05-10 · Sale · Disposed 65,268 · Balance 514,176 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F8: The price reported in Column 4 is a weighted average price per ordinary share ($177.58 per ADS). These shares were sold in multiple transactions at prices ranging from $177.01 per ADS (or $14.75 per ordinary share) to $177.90 per ADS (or $14.83 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 7 · 2019-05-10 · Sale · Disposed 208,260 · Balance 305,916 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F9: The price reported in Column 4 is a weighted average price per ordinary share ($178.60 per ADS). These shares were sold in multiple transactions at prices ranging from $178.02 per ADS (or $14.84 per ordinary share) to $179.00 per ADS (or $14.92 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 8 · 2019-05-10 · Sale · Disposed 145,164 · Balance 160,752 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F10: The price reported in Column 4 is a weighted average price per ordinary share ($179.49 per ADS). These shares were sold in multiple transactions at prices ranging from $179.07 per ADS (or $14.92 per ordinary share) to $180.01 per ADS (or $15.00 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 9 · 2019-05-10 · Sale · Disposed 12,048 · Balance 148,704 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F11: The price reported in Column 4 is a weighted average price per ordinary share ($180.36 per ADS). These shares were sold in multiple transactions at prices ranging from $180.13 per ADS (or $15.01 per ordinary share) to $180.44 per ADS (or $15.04 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 10 · 2019-05-10 · Sale · Disposed 31,368 · Balance 117,336 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F12: The price reported in Column 4 is a weighted average price per ordinary share ($181.46 per ADS). These shares were sold in multiple transactions at prices ranging from $181.28 per ADS (or $15.11 per ordinary share) to $181.65 per ADS (or $15.14 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 11 · 2019-05-10 · Sale · Disposed 10,788 · Balance 106,548 F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F13: The price reported in Column 4 is price per ordinary share converted from price per ADS ($182.32 per ADS).
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-03-15	Direct	0	Reported balance After 2019-05-10 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-05-10 · Exercise / conversion · Disposed 27,419 · Balance 0 F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-03-15	Direct	0	Reported balance After 2019-05-10 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-05-10 · Exercise / conversion · Disposed 365,591 · Balance 0 F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-03-15	Direct	0	Reported balance After 2019-05-10 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2019-05-10 · Exercise / conversion · Disposed 10,788 · Balance 0 F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $10.61 · Expires 2025-06-24	Direct	0	Reported balance After 2019-05-10 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2019-05-10 · Exercise / conversion · Disposed 75,369 · Balance 0 F3: The exercise price was previously reported to be $8.7364 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2026-02-15	Direct	0	Reported balance After 2019-05-10 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2019-05-10 · Exercise / conversion · Disposed 192,755 · Balance 0 F4: The exercise price was previously reported to be $3.3461 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-12-24	Direct	10,603	Reported balance After 2019-05-10 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2019-05-10 · Exercise / conversion · Disposed 6 · Balance 10,603 F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019. F14: These stock options will originally vest on June 24, 2019. Stock options to acquire 6 ordinary shares were accelerated.

Filing footnotes · ownership attribution and instrument terms

F1: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer.

F2: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019.

F3: The exercise price was previously reported to be $8.7364 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error.

F4: The exercise price was previously reported to be $3.3461 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error.

F5: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019.

F6: The price reported in Column 4 is a weighted average price per ordinary share ($175.57 per ADS). These shares were sold in multiple transactions at prices ranging from $174.99 per ADS (or $14.58 per ordinary share) to $175.98 per ADS (or $14.67 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7: The price reported in Column 4 is a weighted average price per ordinary share ($176.40 per ADS). These shares were sold in multiple transactions at prices ranging from $175.99 per ADS (or $14.67 per ordinary share) to $176.87 per ADS (or $14.74 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8: The price reported in Column 4 is a weighted average price per ordinary share ($177.58 per ADS). These shares were sold in multiple transactions at prices ranging from $177.01 per ADS (or $14.75 per ordinary share) to $177.90 per ADS (or $14.83 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F9: The price reported in Column 4 is a weighted average price per ordinary share ($178.60 per ADS). These shares were sold in multiple transactions at prices ranging from $178.02 per ADS (or $14.84 per ordinary share) to $179.00 per ADS (or $14.92 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F10: The price reported in Column 4 is a weighted average price per ordinary share ($179.49 per ADS). These shares were sold in multiple transactions at prices ranging from $179.07 per ADS (or $14.92 per ordinary share) to $180.01 per ADS (or $15.00 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F11: The price reported in Column 4 is a weighted average price per ordinary share ($180.36 per ADS). These shares were sold in multiple transactions at prices ranging from $180.13 per ADS (or $15.01 per ordinary share) to $180.44 per ADS (or $15.04 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F12: The price reported in Column 4 is a weighted average price per ordinary share ($181.46 per ADS). These shares were sold in multiple transactions at prices ranging from $181.28 per ADS (or $15.11 per ordinary share) to $181.65 per ADS (or $15.14 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F13: The price reported in Column 4 is price per ordinary share converted from price per ADS ($182.32 per ADS).

F14: These stock options will originally vest on June 24, 2019. Stock options to acquire 6 ordinary shares were accelerated.

Revance Therapeutics, Inc.

Report date February 04, 2025 · Filed February 06, 2025

Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2025-02-06 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-02-04 · Other · Disposed 30,106 · Balance 15,000 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.

F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	208,260	$14.88	$3,098,908.80	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 7 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,916 F5 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F9 · price: The price reported in Column 4 is a weighted average price per ordinary share ($178.60 per ADS). These shares were sold in multiple transactions at prices ranging from $178.02 per ADS (or $14.84 per ordinary share) to $179.00 per ADS (or $14.92 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	65,268	$14.80	$965,966.40	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 6 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,176 F5 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F8 · price: The price reported in Column 4 is a weighted average price per ordinary share ($177.58 per ADS). These shares were sold in multiple transactions at prices ranging from $177.01 per ADS (or $14.75 per ordinary share) to $177.90 per ADS (or $14.83 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	81,156	$14.70	$1,192,993.20	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 5 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,444 F5 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F7 · price: The price reported in Column 4 is a weighted average price per ordinary share ($176.40 per ADS). These shares were sold in multiple transactions at prices ranging from $175.99 per ADS (or $14.67 per ordinary share) to $176.87 per ADS (or $14.74 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	117,876	$14.63	$1,724,525.88	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 4 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,600 F5 · shares: Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2019. F6 · price: The price reported in Column 4 is a weighted average price per ordinary share ($175.57 per ADS). These shares were sold in multiple transactions at prices ranging from $174.99 per ADS (or $14.58 per ordinary share) to $175.98 per ADS (or $14.67 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	192,755	$3.72	$717,048.60	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 3 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 778,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F4 · price: The exercise price was previously reported to be $3.3461 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	75,369	$10.61	$799,665.09	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 2 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The exercise price was previously reported to be $8.7364 on the Reporting Person's form 3 filed with the SEC on October 1, 2018 due to an administrative error. Read SEC document
May 10, 2019 Filed May 14, 2019 21:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	403,804	$0.00	$524.95	Disclosure SEC source: 0000899243-19-013509 · doc4.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of May 10, 2019. Read SEC document
May 09, 2019 Filed May 10, 2019 20:54 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to buy) · Derivative	9,000	$0.00 Strike: $12.82	$0.00	Disclosure SEC source: 0001479290-19-000056 · wf-form4_155753606689715.xml · derivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-05-08 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 9, 2020, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document
May 09, 2019 Filed May 10, 2019 20:54 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0001479290-19-000056 · wf-form4_155753606689715.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 9, 2020, subject to Mr. Gangolli's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document
March 01, 2019 Filed Mar 6, 2019 22:53 UTC	Krystal Biotech, Inc. KRYS · Entity 3500	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $22.75	$0.00	Disclosure SEC source: 0001209191-19-017476 · doc4.xml · derivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-01 F1 · derivative.exercise_date: The options were awarded on March 1, 2019 and vest monthly over a three-year period. Read SEC document
February 26, 2019 Filed Feb 28, 2019 17:09 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	11,256	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-005266 · doc4.xml · derivative · entry 4 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6 Underlying: Ordinary Shares · 11,256 shares Expires 2020-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.29 U.S. Dollars as of February 26, 2019. Read SEC document
February 26, 2019 Filed Feb 28, 2019 17:09 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	48	$12.37	$593.76	Disclosure SEC source: 0000899243-19-005266 · doc4.xml · nonDerivative · entry 3 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,548 F3 · shares: These ordinary shares are represented by ADSs. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
February 26, 2019 Filed Feb 28, 2019 17:09 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	5,952	$12.45	$74,102.40	Disclosure SEC source: 0000899243-19-005266 · doc4.xml · nonDerivative · entry 2 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,596 F3 · shares: These ordinary shares are represented by ADSs. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
February 26, 2019 Filed Feb 28, 2019 17:09 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	11,256	$0.00	$14.63	Disclosure SEC source: 0000899243-19-005266 · doc4.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · President, North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of stock options. Following the exercise, these shares were converted into 938 American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.29 U.S. Dollars as of February 26, 2019. Read SEC document
May 10, 2018 Filed May 11, 2018 20:27 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to buy) · Derivative	6,000	$0.00 Strike: $29.15	$0.00	Disclosure SEC source: 0001479290-18-000078 · wf-form4_152608484494007.xml · derivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-05-09 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 10, 2019, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document
May 10, 2018 Filed May 11, 2018 20:27 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001479290-18-000078 · wf-form4_152608484494007.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 10, 2019, subject to Mr. Gangolli's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document
May 11, 2017 Filed May 12, 2017 19:48 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $20.90	$0.00	Disclosure SEC source: 0001209191-17-032206 · doc4.xml · derivative · entry 2 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-05-10 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 11, 2018, subject to Mr. Gangolli's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual option grant pursuant to the Compensation Policy. Read SEC document
May 11, 2017 Filed May 12, 2017 19:48 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-032206 · doc4.xml · nonDerivative · entry 1 Gangolli Julian S · CIK 0001532023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 11, 2018, subject to Mr. Gangolli's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.